ARTICLE | Strategy

Merck sticks with MEDI 488 but defers other projects

March 8, 1993 8:00 AM UTC

MedImmune Inc. (MEDI) and Merck have agreed to modify their 1991 agreement to develop monoclonal antibodies for the prevention and treatment of AIDS. Merck will continue to fund its internal development of MedImmune's human MAb MEDI 488, but will defer funding of future research by MEDI on new antibodies...